Latest Press Coverage StablevaX™
Innovate UK Smart Grant awarded to Stablepharma
"[Stablepharma] provides a valid and viable approach which is highly innovative technically, clinically and commercially"
StablevaX™ United States of America patent granted!
"This is really great news for the company, after what has been an 8-year detailed but positive journey with the USPTO"
WHO state that c. 50% of vaccines are wasted due mostly to failures in the cold chain
Stablepharma does not manufacture vaccines, but stands ready to partner with vaccine manufacturers to add our complimentary and enhancing technology to make anti Covid-19 vaccines safe and thermostable information.
The Stablepharma team will continue to work from home and in our laboratory facilities in Europe. We have identified areas which we consider critical to operate and have developed operational continuity plans to ensure we have sufficient resources to keep our R&D work progressing.
We wish to keep our lines of communication open and those needing to contact us are able to do so. Please contact email@example.com
We wish you well during this time of uncertainty but look forward to a positive outcome for all of us.
We have invented a truly disruptive solution that can eliminate the need for refrigeration ('The Cold Chain') and eradicate vaccine wastage once approved
Receive an introduction to Stablepharma pack
Please enter your details below to receive an introduction to Stablepharma